HLH: Does Your Patient Have It? Early Recognition and Evidence-Based Management

Hemophagocytic lymphohistiocytosis (HLH) remains a life-threatening hyperinflammatory syndrome that is frequently underrecognized due to its clinical overlap with sepsis and malignancy-associated complications. This session, led by Dr. Justin Kaner, will explore strategies for early identification of HLH across diverse practice settings, emphasizing practical diagnostic frameworks and timely intervention. Key highlights include updates on the evolving role of biomarkers such as ferritin kinetics, soluble IL-2 receptor levels, and emerging genomic insights in secondary HLH. Recent data from hematology conferences will inform discussion on risk-adapted treatment approaches, including incorporation of targeted therapies such as JAK inhibitors and IFN-γ blockade.